European Medicines Agency (EMA) has accepted to review Pfizer's marketing authorization application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE). BZA/CE is designed for postmenopausal women with a uterus for the treatment of ...
Tags: bazedoxifene conjugated estrogens, BZA/CE, estrogen deficiency symptoms
Wockhardt, a high-technology intensive pharmaceutical and biotechnology company, has gained tentative FDA approval for marketing Ziprasidone, a generic anti-psychotic drug Geodon. The FDA approved generic version of 20mg, 40mg, 60mg and ...
Pfizer has won US FDA approval for its rheumatoid arthritis (RA) therapy, Xeljanz (tofacitinib citrate) 5mg twice daily, indicated for patients who failed to respond to methotrexate. Xeljanz can be used as a single treatment regime or as ...
Tags: Pfizer, tofacitinib citrate, Xeljanz
Nestlé has completed the $11.85bn acquisition of Pfizer Nutrition, following the conclusion of the regulatory process in most markets. Pfizer Nutrition complements Nestlé's existing portfolio with brands in key segments and ...
Tags: Nestlé, acquisition, Pfizer Nutrition, infant cereal
Pfizer has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for crizotinib to treat adults with previously treated anaplastic lymphoma kinase (ALK)-positive ...
Tags: Pfizer, CHMP, anaplastic lymphoma kinase
Pfizer has received positive opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency for the marketing authorization of axitinib to treat patients with advanced renal cell carcinoma. The European ...
Swiss food firm Nestlé has announced that it has completed the acquisition of Pfizer's nutrition division, in a deal valued at $11.85bn, strengthening its position in the global nutrition market. The integration process of Pfizer ...
Tags: Nestlé, food, acquisition, infant nutrition
Bend Research has won two new US patents covering the technology that increases the oral bioavailability of low-solubility drugs. The patents protect compositions and processes for making spray-dried dispersions (SDDs) made with an ...
Tags: patent, pharmaceutical technology, low-solubility drug
The European Commission (EC) has granted marketing authorization to Pfizer's INLYTA (axitinib) oral therapy, designed to treat adult patients with advanced renal cell carcinoma (RCC). INLYTA, a kinase inhibitor, is designed to ...
Teva UK, a part of Teva Pharmaceutical Industries, has introduced the generic atorvastatin film-coated tablets in 10mg, 20mg, 40mg and 80mg strengths in the UK. The generic version of Pfizer's Lipitor is indicated for the treatment of ...
Tags: Teva UK, film-coated tablets, treatment of hypercholesterolaemia
Pfizer is considering buying NextWave Pharmaceuticals, a company that develops a liquid attention deficit hyperactivity disorder drug. In the second quarter of 2012, Pfizer signed an option and merger agreement with NextWave and made a ...
Tags: Pfizer, NextWave Pharmaceuticals, deficit hyperactivity disorder drug
Branham Law Group, a US law firm, is investigating Pfizer for its recall of 14 lots of Lo/Ovral-28 tablet packs and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Pfizer manufactured both drugs and they were marketed in ...
Tags: Investigation, recalls, medical industry
Pfizer is voluntarily recalling its cough syrup medicine, Robitussin DM product, due to errors in its labeling, according to the US FDA . Robitussin DM product contains Dextromethorphan HBr 15mg and Guaifenessin 100mg per 5ml. ...
Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 and 14 lots of Norgestrel and Ethinyl Estradiol tablets in the US due to possibility of inexact tablet counts or out of sequence tablets. The products are indicated for the ...
Pfizer Canada has introduced Toviaz (fesoterodine fumarate extended release tablets) that is indicated for the treatment of patients with overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge incontinence, or any ...
Tags: Pfizer Canada, Toviaz, overactive bladder, OAB